The Filing Desk

Arbutus Biopharma vs Janux Therapeutics

Arbutus Biopharma ABUS · Janux Therapeutics JANX · Biotechnology

Arbutus Biopharma reported revenue of $14 million in fiscal 2025, 1.4 times Janux Therapeutics' $10 million in fiscal 2025. Arbutus Biopharma's revenue grew 128.2% in its latest year, and Janux Therapeutics' fell 5.5%. Arbutus Biopharma had an operating margin of -271.0%, against -1576.7% at Janux Therapeutics. Free cash flow was −$40 million at Arbutus Biopharma and −$83 million at Janux Therapeutics.

Side by side

Arbutus BiopharmaJanux Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$14M$10M
Revenue growth128.2%−5.5%
Revenue growth a year, last 5 years15.4%—
Gross margin——
Operating margin−271.0%−1,576.7%
Net margin−237.9%−1,136.2%
Free cash flow−$40M−$83M
Free cash flow margin−281.4%−832.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.2%15.3%
Last close$4.09$11.37
P/E at the last close3.6×—
Insider trades, last 12 months——
Piotroski F-score3 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arbutus BiopharmaJanux Therapeutics
Operating margin
Percent of revenue
Arbutus BiopharmaJanux Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arbutus BiopharmaJanux Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arbutus Biopharma and Janux Therapeutics pages.